PSTX — Poseida Therapeutics Share News
0.000.00%
Last trade - 00:00- $927.88m
- $755.94m
- $64.70m
Poseida Therapeutics rises on FDA nod to begin cancer therapy study
Brief: Poseida Therapeutics Announces FDA Clearance Of Investigational New Drug Application For P-CD19CD20-ALLO1, An Allogeneic Dual Car-T Cell Therapy For B-Cell Malignancies
Brief: Poseida Therapeutics Receives Notice From Takeda Pharmaceuticals To Terminate Certain Collaboration & License Agreement
Poseida Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Poseida Therapeutics Provides Updates And Financial Results For The First Quarter Of 2023
Poseida Therapeutics Inc expected to post a loss of 45 cents a share - Earnings Preview
Brief: Poseida Therapeutics Appoints Rafael G. Amado, M.D., To Board Of Directors
Poseida Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Poseida Therapeutics Provides Financial Results For The Fourth Quarter And Full Year 2022
Poseida Therapeutics Inc expected to post a loss of 22 cents a share - Earnings Preview
Brief: Poseida Therapeutics Announces Board Change
Brief: Poseida Therapeutics Says Presents Preclinical Data From P-FVIII-101 Gene Therapy For Hemophilia A
Brief: Poseida Therapeutics Presents Early Data From Phase 1 Trials Of P-MUC1C-ALLO1, P-BCMA-ALLO1
Brief: Poseida Therapeutics Provides Updates And Financial Results For The Third Quarter Of 2022
Poseida Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Poseida Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Poseida Therapeutics Inc - Believes Is Well Capitalized With Cash Runway Into At Least Mid-2024
Poseida Therapeutics Inc expected to post a loss of 76 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-U.S. homebuilders, AMC Entertainment